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TRAIL and proteasome inhibitors combination
induces a robust apoptosis in human malignant
pleural mesothelioma cells through Mcl-1 and Akt
protein cleavages
Bao-Zhu Yuan1,2,4*, Joshua Chapman2, Min Ding2, Junzhi Wang1, Binghua Jiang3, Yon Rojanasakul3
and Steven H Reynolds2

Abstract
Background: Malignant pleural mesothelioma (MPM) is an aggressive malignancy closely associated with asbestos
exposure and extremely resistant to current treatments. It exhibits a steady increase in incidence, thus necessitating
an urgent development of effective new treatments.
Methods: Proteasome inhibitors (PIs) and TNFα-Related Apoptosis Inducing Ligand (TRAIL), have emerged as
promising new anti-MPM agents. To develop effective new treatments, the proapoptotic effects of PIs, MG132 or
Bortezomib, and TRAIL were investigated in MPM cell lines NCI-H2052, NCI-H2452 and NCI-H28, which represent
three major histological types of human MPM.
Results: Treatment with 0.5-1 μM MG132 alone or 30 ng/mL Bortezomib alone induced a limited apoptosis in MPM
cells associated with the elevated Mcl-1 protein level and hyperactive PI3K/Akt signaling. However, whereas 10–
20 ng/ml TRAIL alone induced a limited apoptosis as well, TRAIL and PI combination triggered a robust apoptosis in
all three MPM cell lines. The robust proapoptotic activity was found to be the consequence of a positive feedback
mechanism-governed amplification of caspase activation and cleavage of both Mcl-1 and Akt proteins, and
exhibited a relative selectivity in MPM cells than in non-tumorigenic Met-5A mesothelial cells.
Conclusion: The combinatorial treatment using TRAIL and PI may represent an effective new treatment for MPMs.
Keywords: Malignant pleural mesothelioma, Apoptosis, Trail, Proteasome inhibitor, Mcl-1, Akt

Background
Malignant pleural mesothelioma (MPM) is an aggressive
malignancy arising from the mesothelium-lined surfaces
of the pleural cavities following exposure to asbestos [1].
Approximately 3,000 new MPM cases are diagnosed
each year in the United States, with an even higher
number worldwide. Although measures have been put in
place to limit further asbestos exposure, the long latency
of disease development post exposure has resulted in a
dramatically increasing current incidence of MPM [2].
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MPM is extremely resistant to most chemotherapy
regimens examined and not responsive primarily to radiation therapy in general [3,4]. Pemetrexed (Alimta) and
cisplatin combination was shown to be the best chemotherapy regimen for MPM examined so far. However,
median survival with this therapy was less than one year
and the response rate was lower than fifty percent [5].
Targeted therapies, such as anti-angiogenic drugs and
inhibitors of the epidermal growth factor receptor
(EGFR) tyrosine kinase, have proved to be equally ineffective in prolonging MPM patient survival despite substantial over-expression of the relevant molecular targets
in MPM cells [6]. Recent clinical studies showed that
tri-modality therapy with radical pleurectomy, chemotherapy with cisplatin plus pemetrexed or cisplatin plus
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gemcitabine, and radiation can significantly increase median survival rate of MPM patients up to 30 months
from previously less than 12 months with mono-therapy
[7,8]. Nevertheless, it is still urgent to search for effective
new treatments for MPM.
Evasion of apoptosis induction is believed to be a common scheme employed by tumor cells to resist various
treatments [9]. Vast majority of apoptosis are executed
by caspases, which are either the initiator caspases or
effector caspases depending on timing of activation [10].
The intrinsic or mitochondrial apoptosis pathway plays a
fundamental role in various types of apoptosis. Upon
activation, the mitochondria release Cytochrome c (Cyto
c) and Smac/Diablo (Smac) into the cytosol, leading to
sequential activation of caspases 9 and 3/7 and ultimately apoptotic cell death [11,12]. The intrinsic pathway
is regulated mainly by the antiapoptotic members of the
Bcl-2 family proteins, such as Bcl-2, Bcl-XL and Mcl-1
[13]. The extrinsic pathway is responsible for death
receptor-mediated apoptosis. Upon binding by the TNFα
family proteins, death receptor(s) recruit/activate caspase
8/10 through FADD leading to activation of caspase 3/7.
The PI3K/Akt signaling provides important survival
mechanisms in tumor cells by promoting growth and
metastasis, and reducing sensitivity to chemotherapies
[14,15]. The hyperactive PI3K/Akt signaling is commonly seen in MPMs likely due to frequent loss of
PTEN expression [16]. It is also closely associated with
asbestos exposure and SV40 virus infection in the pathogenesis of MPM [17-19]. PI3K/Akt has thus been proposed to be a therapeutic target for MPM [20].
Proteasome inhibitors (PIs) are becoming potential
therapeutic agents for various types of human cancer
that are refractory to conventional chemotherapies [21].
The therapeutic effects of PIs are attributable to their
ability to induce apoptosis [22]. Previous findings have
demonstrated that PIs can induce apoptosis through activating the intrinsic apoptosis pathway, which is under
the regulation by the elevated Mcl-1 protein level following proteasome inhibition [23,24]. However,PIs can also
overcome Mcl-1’s regulation through activation of a
highly efficient positive feedback mechanism (PFM),
which amplifies caspase activation subsequently causing
Mcl-1 protein cleavage [23]. The effect of the PFM is
achieved through linking the initially activated intrinsic
pathway to the extrinsic pathway, thus forming an apoptosis signaling loop and ensuring quick complete apoptotic cell death [23]. PIs can only induce a limited
apoptosis in MPM cells most likely due to their inability
to activate PFM and to cleave Mcl-1 protein [24].
The TNF-related apoptosis inducing ligand (TRAIL) is
a 281-amino acid proapoptotic cytokine of the TNFα
family. After binding to death receptor DR4 or DR5, the
TRAIL protein activates the extrinsic pathway through
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recruiting/activating caspases 8/10 [25,26]. TRAIL plays
an important role in tumor immune surveillance system
by selectively inducing tumor cell apoptosis while leaving normal cells unharmed [25,26]. However, tumor cells
may develop resistance mechanisms to TRAIL-induced
apoptosis at different points along the TRAIL signaling
pathway [25,26].
The combinatorial treatment with TRAIL and PIs
can significantly increase the induction of apoptotic cell
death in some human cancers, including multiple myeloma, renal carcinoma and NSCLC cells, which were not
sensitive to either TRAIL alone or PI alone treatment
[23,27]. However, no attempt has been made to address
the effect of TRAIL and PI combination in MPM cells.
In this study, we show that MPM cells are generally resistant to either PI or TRAIL alone treatment. Both the
hyperactive PI3K/Akt signaling and the concurrently elevated Mcl-1 are responsible for the resistance to PI.
However, the TRAIL and PI combination can induce a
robust apoptotic cell death in all MPM cells. Moreover,
it is believed that the significantly enhanced activity is
achieved through activating the PFM [23] and subsequently cleaving proteins Mcl-1 and Akt. Most importantly, such effect exhibits a relative selectivity in MPM
cells than in non-tumorigenic mesothelial cells, suggesting that TRAIL and PI combination may represent an
effective new treatment for MPMs.

Methods
Materials

Cell lines: Human MPM cell lines NCI-H2052, -H28
and -H2452, the sarcomatoid, epithelial and biphasic (mixed) types of MPM, respectively, and nontumorigenic Met-5A mesothelial cell line were purchased from ATCC and cultured in RPMI 1640 medium
supplemented with 10% FBS. Chemicals: proteasome
inhibitor MG132, caspase inhibitors for wide spectrum
caspases (Z-VAD-fmk), caspase 3 (Z-DQMD-fmk),
caspase 8 (Z-IETD-fmk), caspase 9 (Z-LEHD-fmk) and
caspase 10 (Z-AEVD-fmk), and a negative control (ZFA-fmk), PI3K specific inhibitor LY294002, were from
EMD-CalBiochem (San Diego, CA); proteasome inhibitor Bortezomid was from ChemieTek (Indianapolis, IN);
Mcl-1 siRNA and a negative control siRNA were from
Santa Cruz (Santa Cruz, CA); Soluble recombinant
human TRAIL protein was from R&D Systems (Minneapolis, MN). Antibodies: the antibodies against caspases
3, 7, 9 and 10, PARP, Akt, phospho-Akt at Ser473 (or PAkt), STAT3, phospho-STAT3 at Tyr705 (or P-STAT3)
were from Cell Signaling (Danvers, MA); the antibodies
against caspase 8, Mcl-1 and Bcl-XL were from Santa
Cruz; the antibodies against Bcl-2 and actin were from
Sigma (Milwaukee, WI).
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Western blotting

Procedures of conventional Western blotting were followed to monitor expression and/or cleavage of apoptosisrelated proteins in MPM cells after various treatments.
RIPA buffer supplemented with proteinase inhibitor
cocktail (Sigma, Milwaukee, WI) was used to collect cell
lysates and 10-14% PAGE gels were used to separate
samples before transferring them onto nitrocellulose
membrane. ECL Advance Western Blotting Detection
Kit (GE Healthcare, Piscataway, NJ) was used for
detecting signals.
Cell viability assay

A previously described procedure using WST-1 reagent
(Roche, Indianapolis, IN) was followed to measure cell
viability [24]. Briefly, after various treatments, 0.5-1 ×
104 cells growing in each well of a 96-well microplate
were incubated with 10 μl of WST-1 reagent (Roche,
Indiannapolis, IN) for 1 to 4 hours. Triplicate wells were
set up for each sample in each experiment. The increase
of absorbance at 420 to 480 nm relative to the blank
control was measured for each sample using a microplate spectrophotometer.
Flow cytometry assay

Sub-G0/G1 fraction reflecting DNA fragmentation was
detected in a flow cytometry assay as described previously [24,28]. Briefly, approximately 1 × 105 cells were
collected after treatment, fixed in 70% ethanol, and
stained with propidium iodide, and DNA content was
determined on a flow cytometer (FACSCalibur; BD Biosciences, San Jose, CA).
Akt gene construct and transfection

Mouse wild type Akt (wtAkt) or constitutively active Akt
(myristylated Akt, myr-Akt) cDNA [29] was constructed
in pcDNA3.1Zeo(+) vector and stably transfected into
NCI-H2452 cells following the previously described
procedures [30,31]. The cells selected by Zeocin (25–
100 μg/ml) were tested for their responses to different
apoptosis stimuli.
Mcl-1 silencing

The procedures of siRNA transfection described previously were followed to transfect Mcl-1 siRNA or control
siRNA into NCI-H28 cells [24]. At 36 h after siRNA
transfection, tumor cells were treated and then analyzed
for their responses to different apoptosis inductions. The
siRNA silencing experiment was repeated at least twice.
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GAPDH mRNA expression was used as a control in semiquantitation of PCR products. Primer sequences for
detecting Akt are 50-gctacttcctcctcaagaatgatggc-30 and 50gcagcttcaggtactcaaactcgttc-30 and for GAPDH are 50ggctctccagaacatcatccctgc-30 and 50-gggtgcgctgttgaagtcaga
gg-30.
Statistics

Data for cell viabilities were expressed as the means ±
SD of at least two separate experiments. Comparison
between group means was assessed using a one-way
ANOVA with the Newman-Keuls posttest (GraphPad
Prism 3.0 Software, Inc., San Diego, CA). P < 0.05 was
considered significant.

Results
Proteasome inhibitor MG132 alone or TRAIL alone
induces a limited apoptosis in MPM cells

In this study, we observed that 0.5-1 μM MG132 induced only a limited cell death and protein cleavages in
both NCI-H2452 and NCI-H2052 cells with a greater effect seen in NCI-H2452 cells, but no effects in NCI-H28
cells (Figure 1A & B). Treatment with MG132 significantly elevated Mcl-1 protein level in all three MPM cell
lines with a more significant elevation seen in NCI-H28
and NCI-H2052 cells (Figure 1B), supporting that Mcl-1
is a major regulatory protein against the PI-induced
apoptosis in MPM cells [24].
Since the activated Akt, phospho-Akt (P-Akt), or
STAT3, phospho-STAT3 (P-STAT), confers resistance to
apoptosis through up-regulating the antiapoptotic proteins, such as Mcl-1 in cancer cells [32], to further
understand the resistance of MPM cells to PI-induced
apoptosis, we examined P-Akt and P-STAT3 levels in
the PI-treated MPM cells. A high level of P-Akt was observed in NCI-H28 and NCI-H2052 cells, but not in
NCI-H2452 cells, while a high level of P-STAT3 was
detected in NCI-H2452 and NCI-H2052, but not in
NCI-H28 cells, suggesting that P-Akt is more likely
involved in regulating the PI-induced apoptosis than
P-STAT3 in MPM cells (Figure 1B).
In addition, we found in this study that 10–20 ng/ml
TRAIL alone treatment induced a mild cell death and
protein cleavages in both NCI-H28 and NCI-H2452
cells, but not in NCI-H2052 cells (Figure 2A & B).
TRAIL alone treatment however showed no effect on
Mcl-1 protein expression (Figure 2B).

Semi-quantitative reverse transcription-PCR (RT-PCR)

The TRAIL and PI combination induces a robust apoptosis
in MPM cells through the PFM-governed caspase
activation

Polyadenylated RNA was extracted from NCI-H28 cells
using Trizol reagent and magnetic oligo (dT) beads, and
then used in RT-PCR for detecting Akt gene transcription.

Following single agent alone treatment, we observed that
the combinatorial treatment with 0.5-1 μM MG132 and
10–20 ng/ml TRAIL resulted in a dramatically increased
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Figure 1 MG132 induces a limited apoptosis in MPM cells. (A) Cell viability assay using WST-1 reagent indicates that 0.5-1 μM MG132
induces a significant cell death at 72 h after treatment in both NCI-H2452 and NCI-H2052 cells, but not in NCI-H28 cells. Values are expressed as
the means ± SD of two experiments. *p < .05 versus control. (B) Western blotting demonstrates that 0.5-1 μM MG132 induces protein cleavages for
caspase 3 and PARP at 42 h after treatment in NCI-H2452 and NCI-H2052 cells, but not in NCI-H28 cells. The treatments cause a significant Mcl-1
protein elevation in all three MPM cell lines. NCI-H28 and NCI-H2052 cells exhibit a much higher P-Akt protein level than NCI-H2452 cells, whereas the
P-STAT3 protein is only detectable in NCI-H2452 and NCI-H2052 cells. Protein cleavage fragments in Western blots are indicated by arrows.

cell death and protein cleavages in all three MPM cell lines
with a greater significance seen in NCI-H28 cells (Figure 3A, B & C). Among the proteins undergoing cleavage are
PARP, Bid and caspases 3, 7, 9,10 and Mcl-1 proteins, indicating that both the intrinsic and extrinsic apoptosis pathways were activated by the combinatorial treatment.
To further determine the caspase-dependent nature of
the combinatorial treatment, we chose NCI-H28 cells
for co-treatment using 1 μM MG132 plus 10 ng/ml

TRAIL and 10 μM individual specific inhibitor for
caspase 3, 9, 8 or 10. It was found that inhibition of each
individual caspase significantly reduced both cell death
and protein cleavages (Figure 3D), demonstrating that
the proapoptotic activity of the combinatorial treatment
was caspase dependent with involvement both intrinsic
and extrinsic apoptosis pathways.
It was further observed that, while TRAIL alone induced a limited caspase 10 cleavage only in NCI-H28

Figure 2 TRAIL induces a limited apoptosis in MPM cells. (A) Cell viability assay using WST-1 reagent indicates that 10–20 ng/ml RAIL induces a
significant cell death at 72 h after treatment in NCI-H28 and NCI-H2452 cells, but not in NCI-H2052 cells. Values are expressed as the means ± SD of two
experiments. *p < .05 versus control. (B) Western blotting demonstrates that 10–20 ng/ml TRAIL induces protein cleavage for caspase 3 and PARP at 42 h
after treatment in NCI-H28 and NCI-H2452 cells, but not in NCI-H2052 cells. Protein cleavage fragments in Western blots are indicated by arrows.
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Figure 3 (See legend on next page.)
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(See figure on previous page.)
Figure 3 TRAIL and MG132 (or Bortezomib) combination induces a robust apoptosis in MPM cells. (A) The combinatorial treatment
induces a robust apoptosis in NCI-H28 cells. A-1: Cell viability assay using WST-1 reagent indicates that 10 ng/ml TRAIL and 1 μM MG132
combination induces a dramatic cell death at 72 h after treatment. Values are expressed as the means ± SD of two experiments. *p < .05 versus
control; A-2: Flowcytometry assay demonstrates that the two-agent combination induces a significant increase in DNA damage as indicated by
the sub G0/G1 peak; A-3: Western blotting reveals that the two-agent combination induces a significantly increased protein cleavage for caspases
7, 9 and 10, Bid and PARP in NCI-H28 cells at 24 h after treatment. (B & C) Western blotting demonstrates that the two-agent combination
significantly enhanced apoptosis in both NCI-H2452 and NCI-H2052 cells, as indicated by the enhanced protein cleavage for caspases 3, 9 and 10,
Bid and PARP in NCI-H2452 cells at 36 h after treatment (B) and caspases 7, 9 and 10 and PARP in NCI-H2052 cells at 40 h after treatment (C).
(D) The two-agent-induced-apoptosis is caspase-dependent. Specific inhibitor for the broad spectrum caspases (Z-VAD), caspase 3 (Z-DQMD),
caspase 9 (Z-LEHD), caspase 8 (Z-IETD) or caspase 10 (Z-AEVD) reduces the two-agent-induced cell death (3D-1), as revealed by cell viability assay
at 72 h after treatment, and protein cleavage for caspases 3 and 10, PARP, Mcl-1 and Akt, as demonstrated by Western blotting at 36 h after
treatment. Z-FA is used as a negative control for all caspase inhibitors. *p < .05 versus control. Protein cleavage fragments in Western blots are
indicated by arrows. (E) TRAIL and Bortezomib combination induces a robust apoptosis in NCI-H28 cells with a significant cleavage for both
caspase 10 and Mcl-1 proteins.

cells and showed no effect on Mcl-1 protein level, the
combinatorial treatment dramatically enhanced protein
cleavage for both caspase 10 and Mcl-1, especially in
NCI-H28 cells (Figure 3A). In addition, the increased
protein cleavage for both caspase 10 and Mcl-1 was
completely blocked by the specific inhibitor of each individual caspase (Figure 3D), supporting that the robust
apoptosis was the consequence of activation of the PFM,
which linked both the intrinsic and extrinsic pathways
together leading to quick completion of apoptosis [23].
To test whether other PIs could exhibit a similar robust proapoptotic activity when used in combination
with TRAIL, we chose NCI-H28 as a representative in
the treatment with 30 nM Bortezomib and 5 ng/ml
TRAIL. It was found that the new combinatorial treatment also induced a robust apoptosis in MPM cells with
significant protein cleavage for both Mcl-1 and caspase
10, whereas each single agent induced only a minimal
apoptosis (Figure 3E), suggesting that the induction of
robust apoptosis is a general feature of the PI and
TRAIL combination treatment in MPM cells.

Figure 4 Proapoptotic activities of TRIAL and MG133
combination treatment. Treatment with 10–20 ng/ml TRAIL and
0.5-1 μM MG132 combination reduces protein level for both
phospho- and non-phospho-Akt in NCI-H28 cells, as revealed by
Western blotting at 24 h after treatment.

Reduction of the P-Akt level contributes to the
proapoptotic activity of the combinatorial treatment

In addition to the reduction of Mcl-1 protein level, the
combinatorial treatment also significantly reduced P-Akt
protein level in all three MPM cell lines (Figure 4, using
NCI-H28 as a representative). To determine the involvement of P-Akt in the regulation of apoptosis induction
revealed in this study, we transfected the constitutively
active Akt (or myr-Akt) gene [29] into NCI-H2452
cells, which exhibit much lower endogenous P-Akt level
and are relatively sensitive to either MG132 or TRAIL

Figure 5 The sustained Akt activity confers resistance to
MG132, TRAIL or MG132 plus TRAIL-induced apoptosis to NCIH2452 cells. Western blotting demonstrates that transfection of the
constitutively active Akt (myrAkt) results in a sustained
phosphorylation of Akt at Ser 473 residue and reduces protein
cleavages for caspases 3 and 7 and PARP induced by 1 μM MG132,
10 ng/ml TRAIL or MG132 plus TRAIL.
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treatment (Figures 1 & 2). It was found that the
sustained Akt activity in myr-Akt-transfected cells significantly desensitized NCI-H2452 cells to the apoptosis
induced by MG132, TRAIL or MG132 plus TRAIL
(Figure 5), supporting that the active PI3K/Akt signaling
serves as a critical resistance mechanism against either
PI- or TRAIL-induced apoptosis in MPM cells and can
be reduced by the combinatorial treatment.
The Akt protein is also subjected to the caspasedependent protein cleavage

In the afore-mentioned experiment, it was observed unexpectedly that the protein level of both phospho- and
non-phospho Akt were significantly reduced in NCIH28 cells (Figure 4). Since a semi-quantitative RT-PCR
experiment revealed that treatment with MG132, TRAIL
or MG132 plus TRAIL did not affect Akt transcription,
the possibility of down-regulation of gene transcription
in reducing P-Akt level was thus excluded (Figure 6A).
However, the reduction of P-Akt level was completely
blocked by the specific inhibitors of caspases of either
the intrinsic or extrinsic pathways (Figure 3D), thus
demonstrating that, similar to Mcl-1, the Akt protein is
also subjected to the PFM-governed caspase-dependent
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cleavage in MPM cells following the combinatorial
treatment.

PI3K/Akt and Mcl-1 represent two independent
antiapoptotic mechanisms against the PI-induced
apoptosis in MPM cells

LY294002, a PI3K specific inhibitor, inhibits activities of
the PI3K/Akt signaling [33]. To determine the relationship between Akt and Mcl-1 in regulating PI-induced
apoptosis, we treated NCI-H28 cells with 15 μM LY29
4002 and 1 μM MG132 following Mcl-1 siRNA transfection, which caused more than 50% reduction of Mcl-1
protein expression as determined by the online software
Image J (Figure 6B-1). It was found that, although
LY294002 completely blocked Akt phosphorylation, it
failed to sensitize the cells to MG132 treatment, and
Mcl-1 silencing alone did not sensitize the cells to
MG132 as well. However, Mcl-1 silencing and LY294002
treatment together significantly increased sensitivity
of NCI-H28 cells to the MG132-induced apoptosis
(Figure 6B-2), suggesting that Mcl-1 and PI3/Akt represent two independent critical resistance mechanisms
against PI-induced apoptosis.

Figure 6 The hyperactive PI3K/Akt signaling is responsible for the resistance of MPM cells to MG132-induced apoptosis. (A) TRAIL and
MG132 combination does not affect mRNA expression of the Akt gene in NCI-H28 cells, as indicated by a semi-quantitative RT-PCR at 36 h after
treatment with 1 μM MG132, 10 ng/ml TRAIL or MG132 plus TRAIL. Expression of GAPDH is used as an internal control. (B) Simultaneous
reduction of both P-Akt and Mcl-1 sensitizes NCI-H28 cells to MG132-induced apoptosis: Western blotting demonstrates that simultaneous
reduction of P-Akt by 15 μM LY294002 and Mcl-1 by Mcl-1 siRNA, which results in approximately 50% reduction of Mcl-1 protein expression as
determined by quantitative analysis using the online software Image J (B-1), can induce protein cleavages for caspase 3 and PARP in 1 μM
MG132-treated NCI-H28 cells, whereas reduction of either P-Akt or Mcl-1 is not effective. Protein cleavage fragments in Western blots are
indicated by arrows (B-2).
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The TRAIL and PI combination exhibits a selective activity
in MPM cells

In this study, we also compared apoptotic responses of
non-tumorigenic mesothelial Met-5A cells with that of
MPM cells to the combinatorial treatment. It was found
that Met-5A cells exhibited a much lower amount of cell
death (Figure 7A) and very limited protein cleavages
(Figure 7B) than all three MPM cells to the combinatorial treatment, suggesting that the pro-apoptotic activity
of the combinatorial treatment is more selective in
MPM cells than in normal mesothelial cells.

Discussion
MPM is a very aggressive malignancy with an extreme
resistance to current treatments. Evasion of apoptosis induction due to the inactivated apoptosis machinery and/
or up-regulated anti-apoptotic mechanisms, is largely responsible for its resistance to treatments [24]. A new
treatment with ability to selectively activate the apoptotic machinery while inhibiting multiple antiapoptotic
mechanisms in MPM cells will be a promising candidate
treatment for MPM. This study reveals that the TRAIL
and PI combinatorial treatment can induce a robust
proapoptotic activity in MPM cells of all three major
pathological types, but not in normal mesothelial cells.
The robust activity is achieved through the PFMgoverned caspase activation and subsequent protein
cleavage of both Akt and Mcl-1, the two important antiapoptotic proteins in MPM cells, therefore suggesting
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that the TRAIL and PI combination may serve as a
promising new treatment for MPMs.
The PFM was characterized in a previous study as a
highly efficient apoptosis induction mechanism, [23,24].
It conveys apoptosis signaling from the initially activated
intrinsic pathway to the extrinsic pathway leading to
cleavage/activation of caspase 10/8. The activated extrinsic pathway then forms an apoptosis signaling loop with
the intrinsic pathway through the Bid protein and the
mitochondria. Continuous signaling flow along this loop
results in the amplified caspase activation and subsequent cleavage of the anti-apotpotic protein Mcl-1, thus
ensuring a quick complete apoptotic cell death [23]. The
protein cleavage for both caspase 10 and Mcl-1 can thus
serve as a surrogate indicator of the PFM activation.
Given the observation of a significant elevation in Mcl-1
protein level without caspase 10 cleavage in all three
MPM cells following PI alone treatment, we conclude
that PI alone treatment is insufficient to activate the
PFM and can induce only a limited apoptosis in MPM
cells.
The TRAIL protein induces apoptosis through binding
death receptor DR4/DR5 and then recruiting/activating
caspase 8/10. The TRAIL protein or death receptor
activating antibodies have demonstrated a strong proapoptotic activity in various human cancer cells [25,26].
However, similar to PI alone, TRAIL alone can induce
only a limited apoptosis in MPM cells probably due to
its insufficiency to activate the PFM.

Figure 7 TRAIL and MG132 combination exhibits a selective cell death in MPM cells. (A) Cell viability assay using WST-1 reagent indicates
that 10 ng/ml TRAIL and 1 μM MG132 combination induces a dramatic cell death at 72 h after treatment in all three MPM cells than in Met-5A
cells. (B) Western blotting demonstrates that the combination of 10 ng/ml TRAIL with 1 μM MG132 induces a significant protein cleavage for
caspases 3, 7 and 10 and PARP in all three MPM cell lines, but only induces a slightly visible cleavage for PARP in normal mesothelial Met-5A cell
line. Protein cleavage fragments in Western blots are indicated by arrows.
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Although TRAIL and PI share a limited apoptotic activity in MPM cells, the sensitivity profiles of the MPM
cells are different to these two agents: NCI-H28 cells are
resistant to PIs but mildly sensitive to TRAIL, whereas
NCI-H2052 cells are resistant to TRAIL but slightly sensitive to PI. Such difference reflects a mechanistic discrepancy in apoptosis induction between the two agents
and encourages their combination for achieving an enhanced cell death. Indeed, the compensation can be seen
during the activation of the PFM. Following the PFM
model, it is believed that TRAIL can help PI induce sufficient activation of caspase 3/7 for initiating the PFM,
resulting in caspase 10 activation while reducing Mcl-1
protein level through protein cleavage [23].
The Mcl-1 protein, among the antiapoptotic Bcl-2 and
IAP family proteins, has been characterized to be a
major protein regulating the PI-induced apoptosis in
MPM cells [24]. This specificity is determined largely by
the fact that Mcl-1 is a degradation target of the proteasome [34,35]. The Mcl-1 protein can also be cleaved by
the activated caspase 3 [36]. It is thus not surprising to
observe that proteasome inhibition in the absence of
sufficient caspase 3 activation, as seen in PI alone treatment, elevates Mcl-1 protein level. However, the proteasome inhibition with sufficient caspase 3 activation, as
seen in the combinatorial treatment, reduces Mcl-1 protein level.
Whereas Mcl-1 regulates the PI-induced apoptosis,
the PI3K/Akt signaling regulates both PIs- and TRAILinduced apoptosis in MPM cells. Hyperactive PI3K/Akt
signaling is commonly seen in MPMs due to frequent
loss of PTEN expression [16] and is considered to be a
negative prognosis marker for MPM [37]. This study
reveals that the hyperactive Akt is associated with low
sensitivity of MPM cells to PI-induced apoptosis. In
addition, the sustained Akt activation, as seen in myrAkt-transfected MPM cells, significantly reduces the
sensitivity of tumor cells to PI alone, TRAIL alone, or
even to the combinatorial treatment.
It has been well established that the Akt activity is
most commonly regulated via phosphorylation and dephosphorylation. One consequence of the increased Akt
phosphorylation/activation is the inhibition of its downstream protein GSK3β, which in turn can stabilize Mcl-1
protein from degradation by the proteasome. However,
the present study did not suggest that Akt-GSK3β pathway is involved in regulating Mcl-1 stability in MPM
cells. More likely, Akt and Mcl-1 are separately regulated
in MPM cells and represent two independent resistance
mechanisms to the PI-induced apoptosis, as demonstrated in the experiment using PI3K inhibitor LY294002
and Mcl-1 silencing in PI-treated NCI-H28 cells. It is
possible that, during the regulation of the PI-induced
apoptosis, the elevated Mcl-1 protein level blocks
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pro-apoptotic Bak protein [38], whereas the active Akt
phosphorylate/sequester pro-apoptotic Bad protein from
interacting with Bcl-XL [39].
However, the Akt protein and the Mcl-1 protein share
the same feature of the PFM-directed protein cleavage in
MPM cells following the combinatorial treatment. As
seen in this study, the endogenous Akt protein was
reduced through the caspase-dependent protein cleavage
rather than the reduction of protein phosphorylation or
gene transcription. The involvement of caspase 9 in
the reduction of P-Akt has been seen previously in
UVA-induced apoptosis [40], suggesting that cleavagedependent mechanism may be an alternative mechanism
to the phosphorylation mechanism, especially when the
apoptotic machinery is fully activated by the PFM. Since
several Akt isoforms exist in MPM cells including at
least Akt1 and Akt3 and the antibodies used in the
present study could not distinguish different isoforms
[41], it is of great interest to determine which isoform is
more involved in caspase-dependent regulation.
Consequently, following the PFM model, the increased
caspase activities with the decreased resistance mechanisms of both Akt and Mcl-1 together ensure quick
ultimate apoptotic cell death. More importantly, such
robust proapoptotic activity exhibits a relative selectivity
in MPM cells than in non-tumorigenic mesothelial cells.
However, definitely, the underlying mechanism for the
selectivity warrants further investigation.

Conclusion
The present study demonstrates that the combinatorial
treatment with TRAIL and PI induces a robust apoptosis
more selectively in MPM cells than in normal mesothelial cell, therefore representing an effective candidate
treatment for MPMs. The Akt protein serves as a new
cleavage target of the PFM-directed caspase activation.
In future clinical settings, the protein cleavage for both
Akt and Mcl-1 may be used as effective efficacy marker
to monitor the responses of MPM patients to the combinatorial treatment.
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